Seattle Genetics to Present at Upcoming Investor Conferences

40th Annual Deutsche Bank Health Care Conference
UBS Global Healthcare Conference
Bank of America Merrill Lynch Health Care Conference 2015

BOTHELL, Wash.--()--Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section.

40th Annual Deutsche Bank Health Care Conference
Wednesday, May 6, 9:20 a.m. Eastern Time, Boston

Bank of America Merrill Lynch 2015 Health Care Conference
Thursday, May 14, 10:40 a.m. Pacific Time, Las Vegas

UBS Global Healthcare Conference
Tuesday, May 19, 2:00 p.m. Eastern Time, New York

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The company’s lead product, ADCETRIS® (brentuximab vedotin) is a CD30-targeted ADC that, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available for two indications in more than 50 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials in CD30-expressing malignancies. Seattle Genetics is also advancing a robust pipeline of clinical-stage programs, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME, ASG-15ME and SEA-CD40. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. More information can be found at www.seattlegenetics.com.

Contacts

Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com

Recent Stories

RSS feed for Seattle Genetics, Inc.

Release Summary

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at 3 May investor conferences. Presentations will be webcast live and available for replay at www.seattlegenetics.com

Seattle Genetics, Inc.